Equities research analysts forecast that Kala Pharmaceuticals Inc (NASDAQ:KALA) will announce sales of $2.62 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Kala Pharmaceuticals’ earnings, with the highest sales estimate coming in at $3.25 million and the lowest estimate coming in at $2.00 million. The company is expected to announce its next earnings report on Thursday, August 8th.
On average, analysts expect that Kala Pharmaceuticals will report full-year sales of $12.87 million for the current fiscal year, with estimates ranging from $7.00 million to $15.60 million. For the next year, analysts expect that the business will report sales of $72.89 million, with estimates ranging from $38.90 million to $110.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.75). The firm had revenue of $1.39 million for the quarter, compared to analysts’ expectations of $0.96 million.
In related news, Director Howard B. Rosen purchased 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was acquired at an average price of $5.42 per share, for a total transaction of $27,100.00. Following the completion of the purchase, the director now owns 8,240 shares in the company, valued at $44,660.80. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 30.77% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of the stock. American International Group Inc. increased its stake in shares of Kala Pharmaceuticals by 34.3% in the fourth quarter. American International Group Inc. now owns 10,369 shares of the company’s stock worth $51,000 after buying an additional 2,646 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in Kala Pharmaceuticals by 877.1% during the first quarter. BNP Paribas Arbitrage SA now owns 3,410 shares of the company’s stock valued at $28,000 after purchasing an additional 3,061 shares during the last quarter. Squarepoint Ops LLC increased its stake in Kala Pharmaceuticals by 12.4% during the fourth quarter. Squarepoint Ops LLC now owns 27,871 shares of the company’s stock valued at $136,000 after purchasing an additional 3,071 shares during the last quarter. Rhumbline Advisers increased its stake in Kala Pharmaceuticals by 27.4% during the first quarter. Rhumbline Advisers now owns 19,430 shares of the company’s stock valued at $161,000 after purchasing an additional 4,174 shares during the last quarter. Finally, Patriot Financial Group Insurance Agency LLC bought a new stake in Kala Pharmaceuticals during the first quarter valued at $46,000. Institutional investors and hedge funds own 69.92% of the company’s stock.
Shares of KALA traded down $0.16 during mid-day trading on Tuesday, reaching $5.57. 91,453 shares of the stock traded hands, compared to its average volume of 176,647. The stock has a market cap of $188.73 million, a price-to-earnings ratio of -2.25 and a beta of 2.02. The firm has a fifty day moving average of $5.80. Kala Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $14.45. The company has a current ratio of 10.30, a quick ratio of 9.93 and a debt-to-equity ratio of 0.86.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Recommended Story: Hedge Funds Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.